Cancer immunotherapy: Challenges and limitations

Although cancer immunotherapy has taken center stage in mainstream oncology inducing complete and long-lasting tumor regression, only a subset of patients receiving treatment respond and others relapse after an initial response. Different tumor types respond differently, and even in cancer types tha...

Full description

Saved in:
Bibliographic Details
Published in:Pathology, research and practice research and practice, 2022-01, Vol.229, p.153723-153723, Article 153723
Main Authors: Taefehshokr, Sina, Parhizkar, Aram, Hayati, Shima, Mousapour, Morteza, Mahmoudpour, Amin, Eleid, Liliane, Rahmanpour, Dara, Fattahi, Sahand, Shabani, Hadi, Taefehshokr, Nima
Format: Article
Language:English
Subjects:
CAR T-cell therapy
Humans
Immune checkpoints
Immunotherapy
Neoplasms - therapy
Treatment Failure
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although cancer immunotherapy has taken center stage in mainstream oncology inducing complete and long-lasting tumor regression, only a subset of patients receiving treatment respond and others relapse after an initial response. Different tumor types respond differently, and even in cancer types that respond (hot tumors), we still observe tumors that are unresponsive (cold tumors), suggesting the presence of resistance. Hence, the development of intrinsic or acquired resistance is a big challenge for the cancer immunotherapy field. Resistance to immunotherapy, including checkpoint inhibitors, CAR-T cell therapy, oncolytic viruses, and recombinant cytokines arises due to cancer cells employing several mechanisms to evade immunosurveillance.
ISSN:0344-0338
1618-0631
DOI:10.1016/j.prp.2021.153723